A Phase III trial has demonstrated that zoliflodacin – a single-dose oral antibiotic – is highly effective against drug‐resistant gonorrhea, offering an innovative solution to a mounting public health threat. The encouraging results suggest a potential game‐changer in the fight against antibiotic-resistant infections.
#healthcare #pharmaceuticals #publichealth #drugdevelopment
Saturday, December 13, 2025, 8:21 pm / permalink 16937 / 2 stories in 3 months
Kathleen Medora / aacr - SAN ANTONIO – A mobile health (mHealth) intervention for adolescent and young adult breast cancer survivors that offered tailored support by monitoring electronic patient-reported outcomes (ePROs) significantly improved quality of life and symptoms relate…
Saturday, December 13, 2025, 9:21 am / permalink 16922 / 6 stories in 3 months
Kathleen Medora / aacr - SAN ANTONIO – Using menopausal hormone therapy (MHT) was not associated with an increased risk of breast cancer in women with inherited mutations in the BRCA1 or BRCA2 genes, according to the results of a matched prospective analysis presented at the San …
Saturday, December 13, 2025, 9:21 am / permalink 16921 / 3 stories in 3 months
Kathleen Medora / aacr - Benefit was seen across all subgroups, including in patients with brain metastasis SAN ANTONIO – Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with…
#healthcare #pharmaceuticals #drugdevelopment
Saturday, December 13, 2025, 4:21 am / permalink 16917 / 6 stories in 3 months
go - King Charles III will speak about his cancer diagnosis and recovery during a TV broadcast on Friday as the monarch continues to use his personal story to encourage others to get the early screening that can boost their chances of survival
Saturday, December 13, 2025, 4:21 am / permalink 16916 / 4 stories in 3 months
fiercehealthcare - Dueling partisan proposals to address the expiry of the Affordable Care Act subsidies both failed to advance in the Senate on Thursday.
#healthcare #publichealth #governmentpolicy
Saturday, December 13, 2025, 3:21 am / permalink 16914 / 7 stories in 3 months
medicalxpress - Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers had similar progression-free survival (PFS) whether they were treated with sacituzumab govitecan-hziy (Trodelvy) or standard-of-care chemotherapy as the first treatment af…
#healthcare #pharmaceuticals #drugdevelopment
Saturday, December 13, 2025, 1:21 am / permalink 16912 / 5 stories in 3 months
medicalxpress - Tanning bed use is tied to almost a three-fold increase in melanoma risk, and for the first time, scientists have shown how these devices cause melanoma-linked DNA damage across nearly the entire skin surface, reports a new study led by Northwestern Medic…
Saturday, December 13, 2025, 12:21 am / permalink 16910 / 2 stories in 3 months
HIMSS 2026 pushes real‑time data, cloud and interoperability playbook 14 stories in 18.1 hours
Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma 3 stories in 19.1 hours
Vitamin D trial shows reduced long‑COVID risk but no severity benefit 2 stories in 21.1 hours
Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival 4 stories in 22.1 hours
FDA approves leucovorin for rare folate disorder despite autism hype 4 stories in 34.1 hours
HORMAD1 emerges as a potential target in triple‑negative breast cancer 4 stories in 47.1 hours
Alfasigma pays $300M to GSK for linerixibat rights, expanding liver-disease portfolio 2 stories in 50.1 hours
Roche’s hoped‑for breast cancer pill fails crucial first‑line trial 5 stories in 51.1 hours
Novo Nordisk and Hims bury the hatchet and carve a deal 3 stories in 56.1 hours
AI improves UK breast-screening detection by about 10% 5 stories in 56.1 hours
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.
Bluesky: